<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8728" href="/d/html/8728.html" rel="external">see "Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information"</a> and <a class="drug drug_patient" data-topicid="12320" href="/d/html/12320.html" rel="external">see "Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F10074407"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Voluven [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871155"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Volulyte;</li>
<li>Voluven</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10485746"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Plasma Volume Expander, Colloid</span></li></ul></div>
<div class="block don drugH1Div" id="F53462676"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> With severe dehydration, administer crystalloid first. Dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in critically ill patients, those undergoing open heart surgery with cardiopulmonary bypass, or those with preexisting renal dysfunction. Critical Care Medicine societies (ACCM, SCCM) recommend against the use of hydroxyethyl starch (HES) solutions for fluid resuscitation of severe sepsis and septic shock in neonatal and pediatric patients (ACCM [Davis 2017]; SCCM [Dellinger 2013]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3580eebd-40a6-426b-b15a-00c1e9547c06">Volume expansion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Volume expansion:</b> IV infusion: Usual range: 7 to 25 mL/kg/dose; maximum daily dose: 50 mL/kg/<b>day</b>; in clinical trials of intraoperative use, a dose of 10 mL/kg/dose has been reported (Osthaus 2009; Witt 2008)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F10074443"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> With severe dehydration, administer crystalloid first. Dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do <b>not </b>use in critically ill patients, those undergoing open heart surgery with cardiopulmonary bypass, or those with preexisting kidney dysfunction. Critical Care Medicine societies (ACCM, SCCM) recommend against the use of hydroxyethyl starch (HES) solutions for fluid resuscitation of severe sepsis and septic shock in neonatal and pediatric patients (ACCM [Davis 2017]; SCCM [Dellinger 2013]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3580eebd-40a6-426b-b15a-00c1e9547c06">Volume expansion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Volume expansion:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: IV infusion: Usual range: 7 to 25 mL/kg/dose; mean reported dose: 16 ± 9 mL/kg/dose; maximum daily dose: 50 mL/kg/<b>day</b>; in clinical trials of intraoperative use, a dose of 10 mL/kg/dose has been reported (Chong Sung 2006; Osthaus 2009; Witt 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 12 years: IV infusion: Usual range: 25 to 47 mL/kg/dose; mean reported dose: 36 ± 11 mL/kg/dose; maximum daily dose: 50 mL/kg/<b>day</b>; in clinical trials of intraoperative use, a dose of 10 mL/kg/dose has been reported (Chong Sung 2006; Osthaus 2009; Van der Linden 2013; Witt 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV Infusion: Administer up to 50 mL/kg/<b>day</b> (or up to 3,500 mL daily in a 70 kg patient); may administer repetitively over several days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192969"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Avoid use in patients with pre-existing renal dysfunction; use is contraindicated in oliguric/anuric renal failure unrelated to hypovolemia or patients receiving dialysis. Discontinue use at the first sign of renal injury.</p></div>
<div class="block dohp drugH1Div" id="F51192970"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling; use is contraindicated in severe impairment.</p></div>
<div class="block doa drugH1Div" id="F10074444"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8728" href="/d/html/8728.html" rel="external">see "Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b4f20931-ecbd-4bed-b7d6-07e0ca527bb6">Hypovolemia, plasma volume expansion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypovolemia, plasma volume expansion: Note:</b> Discontinue use at the first sign of kidney injury. With severe dehydration, administer crystalloid first. Do not use in critically ill patients (including those with sepsis or septic shock), or patients with preexisting kidney dysfunction, receiving renal replacement therapy, preexisting bleeding disorders, intracranial bleeding, or severe hepatic dysfunction (SSC [Evans 2021]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 250 to 1,000 mL once; may repeat over several days as needed based on assessment of intravascular volume status. Initial, total volume, and rate of infusion based on clinical situation and individual patient needs; maximum total daily dose: up to 50 mL/kg/day (or up to 3,500 mL/day in a 70 kg patient) (Futier 2020; Guidet 2012; Myburgh 2012; Perner 2012; manufacturer’s labeling).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990901"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Avoid use in patients with preexisting kidney dysfunction. Use is contraindicated in oliguric/anuric kidney failure unrelated to hypovolemia or patients receiving renal replacement therapy. Discontinue use at the first sign of kidney injury.</p></div>
<div class="block doha drugH1Div" id="F50988158"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use is contraindicated in severe hepatic disease.</p></div>
<div class="block adr drugH1Div" id="F10074423"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (dose dependent; may be delayed), skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased serum amylase</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, coagulation time increased, decreased clotting factors, decreased hematocrit, prolonged prothrombin time, wound hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute kidney injury, anaphylactoid reaction, anaphylaxis, bradycardia, bronchospasm, circulatory shock, flu-like symptoms, hemorrhage (perioperative) (Rasmussen 2014), hypersensitivity reaction, hypotension, non-cardiogenic pulmonary edema, shock, tachycardia</p></div>
<div class="block coi drugH1Div" id="F10074418"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to hydroxyethyl starch or any component of the formulation; critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy; kidney failure with oliguria or anuria (not related to hypovolemia); dialysis; any fluid overload condition (eg, pulmonary edema, congestive heart failure); severe hypernatremia; severe hyperchloremia; patients with intracranial bleeding; severe liver disease; preexisting coagulation or bleeding disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Volulyte only: Severe hyperkalemia.</p></div>
<div class="block war drugH1Div" id="F10074419"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid reactions: Anaphylactoid reactions (eg, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, noncardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch; discontinue use immediately with signs of hypersensitivity reaction and administer appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding/coagulopathy: Discontinue use of hydroxyethyl starch (HES) at the first sign of coagulopathy. Monitor the coagulation status in patients undergoing open heart surgery in association with cardiopulmonary bypass. HES solutions have been associated with excess bleeding in these patients. Use is contraindicated in patients with preexisting coagulation or bleeding disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Administration may cause fluid overload; avoid use in patients at risk from overexpansion of blood volume (eg, very young patients, elderly patients). Use is contraindicated in patients with any preexisting condition where volume overload is a potential concern (eg, heart failure, kidney impairment, or renal replacement therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemodilution: Large volumes may cause a reduction in hematocrit, coagulation factors and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; monitor hepatic function. Use is contraindicated in patients with severe hepatic disease; may result in further reduction of coagulation factors, increasing the risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Avoid use in patients with preexisting kidney impairment; fluid status including urine output should be monitored closely; discontinue use at the first sign of kidney injury. Use is contraindicated with oliguria or anuria unrelated to hypovolemia or in patients receiving hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Critically ill patients: HES solutions have been associated with mortality and renal injury requiring renal replacement therapy in critically ill patients, including patients with sepsis; avoid use in critically ill adult patients, including those with sepsis. Avoid use in patients admitted to the ICU (Brunkhorst 2008; Perel 2012; Perner 2012; SSC [Evans 2021]). Crystalloids (eg, sodium chloride and balanced solutions) are recommended as the fluid of choice for initial resuscitation and ongoing resuscitation (SSC [Evans 2021]). If used in patients who are not critically ill, avoid use in patients with preexisting kidney dysfunction and discontinue use at the first sign of kidney injury. Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor kidney function in all patients for at least 90 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Volulyte [CAN]: Contains sodium, magnesium, acetate and potassium; use with caution in situations where electrolyte and/or acid-base disturbances may be exacerbated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not a substitute for red blood cells or coagulation factors. Severely dehydrated patients should be resuscitated with a sufficient volume of crystalloid solution before consideration of tetrastarch administration.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878773"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">HES use has also been associated with acute kidney injury in pediatric patients (Reinhart 2012).</p></div>
<div class="block foc drugH1Div" id="F10074457"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Voluven: 6% (500 mL [DSC]) [dehp free, latex free, pvc free]</p></div>
<div class="block geq drugH1Div" id="F10074410"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322845"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Voluven Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6-0.9% (per mL): $0.12</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871156"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Volulyte: 6% (250 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Voluven: 6% (250 mL, 500 mL)</p></div>
<div class="block adip drugH1Div" id="F53570303"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Voluven: 6% hetastarch (130/0.4) in 0.9% sodium chloride</p>
<p style="text-indent:-2em;margin-left:2em;">Molecular weight: ~130,000</p>
<p style="text-indent:-2em;margin-left:2em;">Sodium: 154 mEq/L</p>
<p style="text-indent:-2em;margin-left:2em;">Chloride: 154 mEq/L</p>
<p style="text-indent:-2em;margin-left:2em;">Osmolarity: 308 mOsm/L</p></div>
<div class="block admp drugH1Div" id="F52614452"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer IV only; may be administered via infusion pump or pressure infusion; if administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Infuse the first 10 to 20 mL slowly to observe for anaphylaxis; have epinephrine and resuscitative equipment available. Do not use if crystalline precipitate forms or is turbid deep brown. Change IV tubing at least once every 24 hours.</p></div>
<div class="block adm drugH1Div" id="F10074450"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer IV only; may be administered via infusion pump or pressure infusion. Infuse the initial 10 to 20 mL slowly while observing for possible anaphylactoid reaction; have epinephrine and resuscitative equipment available. Initial and total volume and rate of infusion is based on clinical situation and individual patient needs. Do not use if crystalline precipitate forms or is turbid deep brown. Change IV tubing at least every 24 hours.</p></div>
<div class="block sts drugH1Div" id="F10074431"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 25°C (59°F to 77°F); do not freeze.</p></div>
<div class="block usep drugH1Div" id="F53570858"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment and prophylaxis of hypovolemia (FDA approved in all ages); <b>Note:</b> Critical Care Medicine societies (ACCM, SCCM) recommend against the use of hydroxyethyl starch (HES) solutions for fluid resuscitation of severe sepsis and septic shock in neonatal, pediatric, and adult patients (ACCM [Davis 2017]; SCCM [Dellinger 2013]; SCCM [Rhodes 2017]).</p></div>
<div class="block mst drugH1Div" id="F50876134"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Voluven may be confused with VoLumen</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300129"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F10140508"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Arbekacin: Tetrastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F14079782"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53570859"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">At baseline and periodically with therapy, measure the following (some parameters may require continuous monitoring): Blood pressure, heart rate, capillary refill time, CVP, RAP, MAP; if pulmonary artery catheter in place, monitor cardiac index, PCWP, SVR, and PVR; hemoglobin, coagulation parameters, renal function (continue to monitor for at least 90 days after administration), urine output, acid-base balance, liver function</p></div>
<div class="block pha drugH1Div" id="F10074432"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces plasma volume expansion by virtue of its highly colloidal starch structure.</p></div>
<div class="block phk drugH1Div" id="F10074434"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: ≥6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 5.9 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Molecules &gt;50,000 daltons are metabolized by plasma α-amylase.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (smaller hydroxyethyl starch molecules [&lt;50,000 daltons] unchanged, metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 31.4 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58845275"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Plasmex | Voluspan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18184958">
<a name="18184958"></a>Brunkhorst FM, Engel C, Bloos F, et al, “Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,” <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/18184958/pubmed" id="18184958" target="_blank">18184958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16451158">
<a name="16451158"></a>Chong Sung K, Kum Suk P, Mi Ja Y, et al, "Effects of Intravascular Volume Therapy Using Hydroxyethyl Starch (130/0.4) on Post-Operative Bleeding and Transfusion Requirements in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial," <i>Acta Anaesthesiol Scand</i>, 2006, 50(1):108-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/16451158/pubmed" id="16451158" target="_blank">16451158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al, "Surviving Sepsis Campaign: International Guidelines For Management of Severe Sepsis and Septic Shock: 2012," <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med.</i> 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31696249">
<a name="31696249"></a>Fleischhacker E, Trentzsch H, Kuppinger D, et al. Fluid resuscitation after severe trauma injury : U-shaped associations between tetrastarch dose and survival time or frequency of acute kidney failure. Therapie des Volumenmangelschocks nach Polytrauma : U-förmige Assoziation zwischen Tetrastärke(HES)-Dosis und Überlebenszeit bzw. Häufigkeit eines akuten Nierenversagens. <i>Med Klin Intensivmed Notfmed</i>. 2020;115(7):591-599. doi:10.1007/s00063-019-00625-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/31696249/pubmed" id="31696249" target="_blank">31696249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31961418">
<a name="31961418"></a>Futier E, Garot M, Godet T, et al. Effect of hydroxyethyl starch vs saline for volume replacement therapy on death or postoperative complications among high-risk patients undergoing major abdominal surgery: the FLASH randomized clinical trial. <i>JAMA</i>. 2020;323(3):225-236. doi:10.1001/jama.2019.20833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/31961418/pubmed" id="31961418" target="_blank">31961418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22624531">
<a name="22624531"></a>Guidet B, Martinet O, Boulain T, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. <i>Crit Care</i>. 2012;16(3):R94. doi:10.1186/cc11358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22624531/pubmed" id="22624531" target="_blank">22624531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19114887">
<a name="19114887"></a>Hanart C, Khalife M, De Villé A, et al, "Perioperative Volume Replacement in Children Undergoing Cardiac Surgery: Albumin Versus Hydroxyethyl Starch 130/0.4," <i>Crit Care Med</i>, 2009, 37(2):696-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/19114887/pubmed" id="19114887" target="_blank">19114887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26774199">
<a name="26774199"></a>Lagny MG, Roediger L, Koch JN, et al. Hydroxyethyl starch 130/0.4 and the risk of acute kidney injury after cardiopulmonary bypass: a single-center retrospective study. <i>J Cardiothorac Vasc Anesth</i>. 2016;30(4):869-875. doi:10.1053/j.jvca.2015.10.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/26774199/pubmed" id="26774199" target="_blank">26774199</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lochbuhler H, Galli C, and Hagemann H, "Hydroxylethyl Starch HES 130/0.4 in Paediatric Surgery: Results on an Explorative, Controlled, Multicenter Safety Study," <i>Crit Care</i>, 2003, 7(2 Suppl):107.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23075127">
<a name="23075127"></a>Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation inintensive care. <i>N Engl J Med</i>. 2012;367:1901-1911. doi:10.1056/NEJMoa1209759<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/23075127/pubmed" id="23075127" target="_blank">23075127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19173690">
<a name="19173690"></a>Osthaus WA, Witt L, Johanning K, et al, "Equal Effects of Gelatin and Hydroxyethyl Starch (6% HES 130/0.42) on Modified Thrombelastography in Children," <i>Acta Anaesthesiol Scand</i>, 2009, 53(3):305-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/19173690/pubmed" id="19173690" target="_blank">19173690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696320">
<a name="22696320"></a>Perel P and Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. <i>Cochrane Database Syst Rev.</i> 2012;6:CD000567. doi:10.1002/14651858.CD000567.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22696320/pubmed" id="22696320" target="_blank">22696320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22738085">
<a name="22738085"></a>Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate insevere sepsis. <i>N Engl J Med.</i> 2012;367:124-134. doi:10.1056/NEJMoa1204242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22738085/pubmed" id="22738085" target="_blank">22738085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24100337">
<a name="24100337"></a>Rasmussen KC, Johansson PI, Højskov M, et al. Hydroxyethyl starch reduces coagulation competence and increases blood loss during major surgery: results from a randomized controlled trial. <i>Ann Surg</i>. 2014;259(2):249-254. doi:10.1097/SLA.0000000000000267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/24100337/pubmed" id="24100337" target="_blank">24100337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22323076">
<a name="22323076"></a>Reinhart K, Perner A, Sprung CL, et al, “Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,” <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22323076/pubmed" id="22323076" target="_blank">22323076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18647272">
<a name="18647272"></a>Sümpelmann R, Kretz FJ, Gäbler R, et al, “Hydroxyethyl Starch 130/0.42/6:1 for Perioperative Plasma Volume Replacement in Children: Preliminary Results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS),” <i>Paediatr Anaesth</i>, 2008, 18(10):929-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/18647272/pubmed" id="18647272" target="_blank">18647272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23934169">
<a name="23934169"></a>Van der Linden P, De Villé A, Hofer A, Heschl M, Gombotz H. Six percent hydroxyethyl starch 130/0.4 (Voluven®) versus 5% human serum albumin for volume replacement therapy during elective open-heart surgery in pediatric patients. <i>Anesthesiology</i>. 2013;119(6):1296-1309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/23934169/pubmed" id="23934169" target="_blank">23934169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28077532">
<a name="28077532"></a>Vives M, Callejas R, Duque P, et al. Modern hydroxyethyl starch and acute kidney injury after cardiac surgery: a prospective multicentre cohort. <i>Br J Anaesth</i>. 2016;117(4):458-463. doi:10.1093/bja/aew258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/28077532/pubmed" id="28077532" target="_blank">28077532</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Voluven (tetrastarch) [prescribing information]. Lake Forest, IL: Hospira, Inc; February 2015.</div>
</li>
<li>
<div class="reference">
                  Voluven (tetrastarch) [prescribing information]. Lake Forest, IL: Hospira, Inc; July 2014.</div>
</li>
<li>
<div class="reference">
                  Voluven (tetrastarch) [product monograph]. Ontario, Canada: Fresenius Kabi Canada; March 2015.</div>
</li>
<li>
<div class="reference">
                  Volulyte (tetrastarch) [product monograph]. Toronto, Ontario, Canada: Fresenius Kabi Canada Ltd; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18811828">
<a name="18811828"></a>Witt L, Osthaus WA, Jüttner B, et al, "Alteration of Anion Gap and Strong Ion Difference Caused by Hydroxyethyl Starch 6% (130/0.42) and Gelatin 4% in Children," <i>Paediatr Anaesth</i>, 2008, 18(10):934-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/18811828/pubmed" id="18811828" target="_blank">18811828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23423413">
<a name="23423413"></a>Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. <i>JAMA</i>. 2013;309(7):678-688. doi:10.1001/jama.2013.430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/23423413/pubmed" id="23423413" target="_blank">23423413</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16069 Version 130.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
